Mevacor Panelists Discuss Rx Formulary, OTC Cost Concerns
This article was originally published in The Tan Sheet
Executive Summary
Mevacor Daily could complicate physician prescribing practices related to prior authorization for Rx statins if the drug were approved for over-the-counter sale
You may also be interested in...
Mevacor OTC Panel Rejection Elicits Third Drug Class Talk
A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists
Healthcare Payers Split On Promoting OTC Statin Use – Survey
Half of healthcare payers questioned in a recent survey say they would educate members about nonprescription statins if an OTC product were to reach the market, according to a report in the November/December Journal of Managed Care Pharmacy
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC